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Abstract
This was a double-blind placebo-controlled study with a
cross-over design to examine the effects of scopolamine
on cognitive functions in young healthy subjects. Sco-
polamine hydrobromide was administered subcuta-
neously to 12 subjects (mean B SD age 23.8 B 2.2 years)
at doses of 0.3 and 0.6 mg in comparison with two place-
bo conditions. Scopolamine at both doses produced
marked sedation as rated by subjects and an observer. In
the continuous performance test, vigilance was impaired
by both doses of scopolamine. The span of apprehen-
sion test showed differing results (only the high dose of
scopolamine showed a performance decrement only in
the three-character version of the span of apprehension
test). Significant impairment by both doses of scopol-
amine was seen in immediate and delayed free recall,
continuous visual recognition, running word recognition
and running picture recognition. While scopolamine
caused a significant slowing in average reaction times
for simultaneous matching as well as for delayed match-
ing, subjects made more errors under scopolamine com-
pared to placebo only in delayed matching, not in simul-
taneous matching. Also, the main outcome of matching
to sample showed significant effects only in delayed
matching, not in simultaneous matching. Notable in this
study is the incongruity between the simultaneous
matching test and the span of apprehension test on the
one hand and the other cognitive tests used on the other.
These results demonstrated that scopolamine has a
greater effect on memory than on attention. Thus, the
scopolamine-induced effects in the present study seem
to be more relevant to Alzheimer’s disease in an ad-
vanced phase than to normal aging.
Copyright © 2003 S. Karger AG, Basel
Introduction
Two aspects of scopolamine action on cognition have
been discussed controversially in recent years. The drug
effect has been discussed as a model for memory deficits
seen in patients with Alzheimer’s disease [1] or a more
general model for cognitive deficits associated with nor-
mal aging [2–5]. In a comprehensive battery of cognitive
tasks, scopolamine was shown to produce the same defi-
cits as normal aging [3]. Errors of intrusion, decreased dig-
it span and impaired object naming, frequently found in
patients with Alzheimer dementia, were not seen after dif-
ferent doses of scopolamine injections. Thus, it seems that
scopolamine mimics some but not all relevant aspects of
cognitive deficits seen in patients with early Alzheimer’s
disease. The question is, which aspects of normal aging
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are close to those observed after scopolamine administra-
tion. Callaway et al. [4] showed that scopolamine failed to
impair performance in an age-sensitive task of rapid
visual information processing (span of apprehension
test).
Scopolamine has been shown to significantly lower
stimulus sensitivity and to prevent the rise bias, which
occurred in the placebo condition [6]. Some former stud-
ies demonstrated that there is a significant overall correla-
tion between age and scopolamine effects on psychomotor
speed, short-term recall, visual tracking speed, viso-motor
coordination and sequencing ability [7]. These findings
need further evaluation.
Furthermore, there has been discussion whether sco-
polamine effects are primarily in the domain of attention
or of memory and if there is any causal relationship
between both aspects of cognition [5, 8–11]. It has been
argued that larger doses of scopolamine are required to
impair memory performance than to produce decrements
in arousal [12]. Coadministration of drugs with attention-
enhancing effects like amphetamine or nicotine, however,
did reverse scopolamine-induced memory deficits in free
recall [13]. Scopolamine- or lorazepam-induced sedation
(rated by the subject or measured by motor retardation)
was found to be more closely related to performance on
attention and psychomotor tasks than to performance on
memory tasks [5]. In some studies, cholinergic drugs have
been shown to have an effect on both attentional and
memory aspects of information processing [14].
The matching to sample paradigm could be helpful in
distinguishing the attentional and amnesic action of sco-
polamine in information processing. Performance on this
task is particularly sensitive to damage of the medial tem-
poral lobe, including those regions vulnerable to Alzhei-
mer’s disease [15]. The paradigm was first described in a
scopolamine study with monkeys [16]. The animals were
shown a 3-second illumination of one of nine panels on a
three-by-three display. Following a variable delay, the ani-
mals were given access to the panel and were rewarded for
a correct response. In humans, a slightly different version
is used, which implies the presentation of several visual
choice stimuli either simultaneously with a target stimu-
lus (also called visual discrimination), immediately after
the target stimulus has disappeared (0 s delay) or after lon-
ger delays, generally up to 30 s [17, 18]. The paradigm can
be used in animal studies (nonmatching, e.g. pointing to
the novel stimulus) as well as in human studies (matching,
e.g. pointing to the sample stimulus). In several human
studies, selective impairment by lorazepam [19] and by
scopolamine [3, 8] in the delayed matching to sample task
has been found, which is interpreted as an indicator of a
selective amnesic action of both drugs.
In a recent study [20], it was shown that scopolamine
can produce selective deficits in tests of short-term visual
recognition memory that do not depend on overall im-
pairment of arousal.
In humans, there is evidence that scopolamine impairs
the acquisition of information and attentional functions
as well as producing anterograde amnesia. The exact
interrelationship between these effects is still unknown.
Even less clear is the nature of the neural substrates for
these different effects.
In this study, we examined the effects of scopolamine
on memory and attention. We used the matching to sam-
ple paradigm for the measurement of scopolamine-in-
duced deficits by the concurrent measurement of atten-
tion and memory with a battery of tests that have pre-
viously shown effects of scopolamine or lorazepam [10,
19, 21, 22]. In this study, effects of scopolamine on mem-
ory were tested by immediate and delayed free recall, con-
tinuous visual recognition, running word recognition and
running picture recognition. Effects on attention were
tested by a continuous performance test and by a span of
apprehension test. The matching to sample paradigm can
be helpful in distinguishing attentional and memory ef-
fects. The selection of tests was guided by the question
whether scopolamine-induced cognitive deficits in young
subjects are similar to normal aging or to Alzheimer’s dis-
ease, i.e. to test whether attentional and memory deficits
are related or differently affected.
Methods
Subjects
Twelve healthy volunteers (8 females, 4 males; mean age 23.8 B
2.2 years; mean years of education 15.8 B 2.2) participated in the
study. Volunteers were intensively screened by a physical and psy-
chiatric examination performed by an experienced psychiatrist to
exclude those with medical or psychiatric illness. The body weight of
the subjects ranged from 50 to 76 kg (mean 66.3 B 7.3 kg). The sub-
jects’ intelligence was above average (mean Leistungsprüfsystem IQ
[23] 124.5 B 9.6), and so was their memory performance [mean
number of words recalled in the first trial of the Auditory Verbal
Learning Test (AVLT) was 10.2 B 2.1, and in the fifth trial of the
AVLT, it was 15.4 B 0.9]. Average performance of the AVLT was
performed [24, 25]. The defined protocol was approved by the Facul-
ty Medical Ethics Committee and all subjects signed informed con-
sent prior to participation.
Design and Dosing
The study was double blind, randomized and used a Latin square
design. Each subject received four subcutaneous injections (two pla-
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cebo injections, plus 0.3 and 0.6 mg of scopolamine hydrobromide)
at weekly intervals.
Procedure
On the screening day, subjects underwent a medical and psycho-
logical examination and a training session on the computerized task
with items different from those used on the test day. On all of the four
experimental days, however, the same items were used. Presentation
time in the continuous performance test was generally 40 ms. For
subjects who had less than 75% hits on the screening day, presenta-
tion time was 70 ms on all experimental days. There was a further
training session for the continuous performance test on each of the
experimental days. Four word lists were used for free recall. The first
word list was presented 3 min before drug injection. The second,
third and fourth word lists were presented 82, 137 and 213 min after
drug injection, respectively, one at a time (table 1). For visual acuity,
subjects had to determine the position of a variable gap in automati-
cally presented circles. At the end of each session, subjects and an
observer were asked to judge if placebo or scopolamine had been
applied. Item presentation and data collection were controlled by an
IBM-compatible PC.
Mood Assessment
For mood evaluation, the 15 items of the EWL-G (Eigenschafts-
wörterliste; adjective check list) [26] and three further items (wake-
fulness, physical well-being, effectiveness) were presented on seven-
point rating scales to subjects and to an observer. Answers were given
on a seven-point rating scale between ‘absolutely true’ and ‘absolute-
ly not true’. Additionally, an observer rated the subjects’ personality
and test behavior (understanding of test instructions, willingness to
continue, interest in own performance, cooperation, conscientious-
ness, motivation, self-criticism, stress resistance, nervousness,
amount of complaining and ambition). The questions were the same
for each test day.
Attention
Continuous Performance Test. The continuous performance test
goes back to Rosvold et al. [27] and was reintroduced by Nuechter-
lein [28, 29] as a vigilance test. The continuous performance test
measures sustained attention. Digits (0–9) are presented tachistosco-
pically on a screen against a noise background. Digits appear in a
random sequence over 8 min and at a rate of one digit per second.
The subjects are required to press a button whenever a particular
target digit (the number zero) appears. A total of 120 target digits and
360 nontargets are presented. The nonparametric measure of sensi-
tivity is used as a measure of outcome. We used A to designate the
nonparametric measure of sensitivity for the continuous perfor-
mance test.
Span of Apprehension Test. The procedure is adapted from that
reported by Estes and Taylor [30]. The span of apprehension test is
created to show effects on attention. This test is used to measure the
number of items which a person can recognize at the same time. 80
sets of characters are consecutively shown for 100 ms each. Each set
of characters consists of 3 or 8 characters and comprised either the
character F or T, never both together. Subjects have to decide which
of the two characters has been presented. Alternatively, 10 sets with
three and 10 sets with 8 characters are shown over 8 min. ISI was 2 s,
but was prolonged occasionally until the subject pressed one of the
two buttons. The percentage of hits is used as a measure of outcome.
Table 1. Experimental schedule
Time (min) Procedure
U3 Word list 1
B0 Drug injection
V10 Training of continuous performance test
V18 Break
V58 Learning trial of running word recognition
V68 Learning trial of running picture recognition
V82 Word list 2
V85 Break
Block 1
V90 Mood evaluation
V92 Running word recognition
V96 Running picture recognition
V103 Simultaneous matching
V105 Delayed matching
V113 Continuous visual memory
V122 Break
V137 Word list 3
V140 Visual acuity
V143 Continuous performance test
V151 Span of apprehension test
V159 Mood evaluation by an observer
V159 Break
Block 2
V179 Mood evaluation
V181 Running word recognition
V185 Running picture recognition
V192 Simultaneous matching
V194 Delayed matching
V202 Continuous visual memory
V211 Delayed free recall of word lists 1–3
V213 Word list 4
V216 Test behavior evaluation by an observer
V223 Side effect evaluation
Memory
Immediate and Delayed Free Recall. Four lists of 24 new words
each are matched for frequency of occurrence in the German lan-
guage, word length and imagery. The lists were read before injection
and 80, 140 and 210 min after injection. The same word lists were
used every test day. The words are read aloud at a rate of one word
every 2 s. Immediate written recall in any order is required. The dif-
ference between total correct recall and omission errors is used as a
measure of outcome for free recall. For delayed free recall, subjects
are asked to write in any order as many of the words as they could
remember from the first three lists (table 1). The number of correctly
remembered words from each list is used as a measure of outcome for
delayed free recall (table 1).
Continuous Visual Recognition. The continuous visual recogni-
tion task is a memory test. In each test block, a new list of 108 pic-
tures is presented continuously on the screen. In each list, 18 target
stimuli appear for a second time. The interval between the first and
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second presentation of the target stimuli varies between 10 and 20
items. The target stimuli are spread over the whole list. For each tar-
get stimulus, four distractors are constructed with decreasing similar-
ity to the target stimulus. One to four distractors are presented only
after the first presentation of the corresponding target stimulus and
before the second presentation of the target stimulus. Each item is
presented on the screen for up to 10 s or until subjects press one of the
two buttons (item presented for the first or for the second time),
whichever comes first. Hits minus false alarms were used as a mea-
sure of outcome.
Running Word Recognition. The running word recognition test
measures memory effects. Two hundred nouns with a frequency of
usage greater than 1: 110.000 [28] were selected and randomly allo-
cated to a preliminary list and two test lists. The 50 new words in
each list are mixed with 50 old words from the preceding list. Thus,
in each block, 100 words are presented visually for a maximum of 6 s.
The subject’s task is to classify each word as ‘old’ or ‘new’. Hits minus
false alarms were used as the measure of outcome.
Running Picture Recognition. The running picture recognition
test measures memory effects. The structure of the running picture
test is the same as for running word recognition. For test construc-
tion, 200 different pictures are used. Both running recognition tasks
as well as the matching to sample tasks are part of the Computeri-
sierte Gedächtnis und Aufmerksamkeitstest (München) [CGT-(M)],
an automated memory test.
Matching to Sample
This test consists of four parallel matching to sample tasks (2 !
simultaneous matching to sample, 2 ! delayed matching to sample),
each consisting of 18 items. Each item consists of a target stimulus
and a set of four simultaneously presented, numbered choice stimuli
(one target stimulus and three distractors). Target stimuli consist of
motivating abstract and realistic colored pictures (60 ! 60 mm), and
the distractors differ from target stimuli to some degree in color, size
or content. Each item is presented on the screen for up to 20 s or until
subjects press the correct button, whichever comes first. If the
response is an error, the item remains on the screen and subjects can
choose again. In the simultaneous matching task, the 18 items consist
of a target stimulus in the left half of the screen and four choice stim-
uli on the right. In the delayed matching task, a target stimulus is
shown for 4 s, followed by 15 s of tone distraction. For tone distrac-
tion, high (700-Hz) and low (300-Hz) tones with a duration of 250 ms
and ISI of 800–3,000 ms are presented at an average ratio of 1.2.
Subjects are instructed to react to the tones. Then the four choice
stimuli are presented simultaneously and subjects are requested to
press the corresponding button as quickly as possible. For matching
to sample tasks, median reaction time to correct response, errors and
points are calculated. Points are computed a priori as follows: for a
correct response during the first second, 30 points were given, for a
correct response during the following second, 29 points were given. A
correct response on the second key press received a score 10 points
lower. A correct response on the third, fourth or fifth key press
received 0 points. Thus, a fast and correct response received the high-
est number of points.
Statistical Analyses
For the main analysis of treatment effects, the results of tests per-
formed 58–216 min after drug intake were averaged. These data were
subjected to analyses of variance. The design was that of a Latin
square factorial design, testing the effects of drugs and test days. The
following post hoc comparisons were calculated: placebo 1 versus
placebo 2; low-dose scopolamine versus mean placebo; high-dose
scopolamine versus mean placebo, and high-dose scopolamine ver-
sus low-dose scopolamine. The statistical significance of these post
hoc comparisons was corrected using Bonferroni adjustment, i.e. by
dividing the nominal significance level by the number of compari-
sons. The result of post hoc comparisons is reported as statistically
significant only when p ! 0.0125.
Results
The effects of scopolamine on visual acuity were not
statistically significant (F(3,24) = 0.8; p = 0.483). All sub-
jects and an observer were perfectly able to distinguish
between placebo and verum on all study days (100% cor-
rect guessing). There were no significant differences be-
tween the two placebo conditions for any of the measures.
All results are shown in table 2.
Mood Evaluation
Scopolamine caused a marked sedation on self-rating
and even more on observer rating of mood, when com-
pared to placebo. Generally, there were main drug effects
for 14 items in self-ratings of mood and 23 items for
observer ratings of mood, where most items dealt with a
reduction of alertness, effectiveness, concentration and
cheerfulness and an increase in social withdrawal. The
most affected single item on self-rating and observer rat-
ing was drowsiness.
Attention
Continuous Performance Test. Vigilance was impaired
under both doses of scopolamine in comparison with pla-
cebo. The results for scopolamine 0.3 mg versus placebo
reached significance, as did those for scopolamine 0.6 mg
placebo (p ! 0.01 each).
Span of Apprehension Test. In comparison with place-
bo, only the high dose of scopolamine (0.6 mg) produced a
performance decrement in the three-character, but not in
the eight-character version of the task (p ! 0.05).
Memory
Immediate and Delayed Free Recall. In immediate free
recall as well as delayed free recall, there was a significant
difference between scopolamine 0.3 mg and placebo as
well as scopolamine 0.6 mg and placebo (p ! 0.001 each).
Differences were shown between the 4 word lists used.
While there were no drug-related differences in the imme-
diate recall of the first word list (F (3,24) = 0.0; p = 0.997),
immediate recall was markedly reduced in the drug-active
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Table 2. Effects of scopolamine on sedation, attention, memory and matching to sample
Placebo 1 Placebo 2 p1 Scopolamine
0.3 g
p2 Scopolamine
0.6 g
p3 p4 Factor drug
F (3,24) p
Day
F (3,24) p
Retest
reliability
Sedation1
Self-rating of sedation 2.8 (0.8) 3.1 (1.0) NS 4.8 (1.2) *** 5.1 (0.6) *** NS 25.8 !0.001 1.3 NS 0.38
Observer rating of sedation 2.5 (1.1) 2.9 (0.7) NS 4.7 (1.1) *** 6.2 (0.5) *** *** 63.3 !0.001 2.4 NS 0.48
Attention
CPT(A) 0.91 (0.06) 0.92 (0.08) NS 0.84 (0.08) ** 0.84 (0.11) ** NS 6.9 0.002 5.6 0.005 0.80
SAT 3, % hits 94.8 (4.9) 94.1 (5.4) NS 92.7 (5.6) NS 90.8 (6.2) * NS 3.6 0.027 3.8 0.024 0.39
SAT 8, % hits 80.8 (11.5) 81.5 (8.4) NS 82.0 (7.4) NS 76.8 (10.9) NS NS 1.5 NS 2.4 NS 0.39
Memory
Immediate free recall (correct) 12.2 (2.4) 11.5 (3.8) NS 9.1 (3.6) *** 5.9 (2.7) *** *** 26.2 !0.001 8.8 !0.001 0.64
Delayed free recall (correct) 6.8 (3.2) 6.1 (2.8) NS 4.4 (3.3) *** 3.3 (1.6) *** * 19.8 !0.001 14.6 !0.001 0.92
Visual recognition (hits – FA) 0.38 (5.5) 1.16 (5.1) NS –1.37 (5.9) NS –5.12 (8.8) *** ** 10.6 !0.001 30.0 !0.001 0.79
Word recognition (hits – FA) 19.7 (6.8) 20.3 (4.0) NS 17.2 (6.0) NS 11.5 (4.7) *** ** 11.2 !0.001 2.2 NS 0.56
Picture recognition (hits – FA) 31.0 (6.1) 30.1 (4.6) NS 27.6 (4.8) ** 21.9 (5.6) *** *** 24.6 !0.001 12.0 !0.001 0.52
Matching to sample
Simultaneous, s 2.4 (0.7) 2.4 (0.3) NS 2.5 (0.6) NS 3.1 (0.5) *** *** 11.5 !0.000 14.9 !0.000 0.56
15-second delayed, s 2.5 (0.9) 2.3 (0.5) NS 2.7 (0.7) NS 3.2 (0.7) *** * 6.1 0.003 7.8 0.001 0.72
Simultaneous, errors 1.8 (1.0) 1.6 (1.3) NS 2.4 (1.4) NS 2.0 (1.5) NS NS 1.1 NS 0.4 NS 0.60
15-second delayed, errors 3.9 (1.9) 4.0 (1.8) NS 8.0 (3.2) ** 6.4 (2.3) ** NS 6.0 0.003 1.0 NS 0.65
Simultaneous, points 475.3 (18.4) 475.3 (23.6) NS 469.9 (17.9) NS 460.6 (21.6) * NS 2.6 NS 8.8 0.001 0.46
15-second delayed, points 453.9 (27.7) 450.6 (39.6) NS 427.2 (30.2) ** 416.6 (25.3) *** NS 8.1 0.001 5.2 0.007 0.83
Values are group means (SD in parentheses), ANOVA results and retest reliability of measures. Asterisks indicate the uncorrected significance of the four comparisons:
placebo 1 versus placebo 2 (p1), scopolamine 0.3 mg versus mean placebo (p2), scopolamine 0.6 mg versus mean placebo (p3), and scopolamine 0.3 mg versus scopolamine
0.6 mg (p4). * p ! 0.05, ** p ! 0.01, *** p ! 0.001. None of the interactions was significant. NS = Not significant; CPT = continuous performance test; SAT = span of
apprehension test; FA = false alarms.
1 The following items with seven-point scales were combined into a single score (1 = no sedation): widely awake, very effective, very active, very attentive, not sluggish, not
exhausted, not drowsy, and not dreamy.
time for word list 2 (F (3,24) = 20.4; p ! 0.001) and word
list 4 (F (3,24) = 23.2; p ! 0.01). In addition, there was a main
effect of scopolamine on delayed recall. 211 min after
intake of either 0.3 or 0.6 mg of scopolamine, subjects
recalled on average 1.2 and 0.7 words more, respectively,
from the first word list learned 3 min before drug injection
than under placebo. This effect of retrograde hypermnesia,
however, failed to reach significance 4 (F (3,24) = 1.0; p !
0.405). These results are shown in figure 1.
Continuous Visual Recognition. There was a main
effect of drug condition on this measure. Subsequent con-
trasts only showed a reduced performance under the high
dose of scopolamine. Main drug effects for the first block
(F (3,24) = 6.3; p ! 0.003) were comparable to those of the
second block (F (3,24) = 6.0; p ! 0.003).
Running Word Recognition. Again there was a main
effect of drug condition on this task and a reduced perfor-
mance only under the high dose of scopolamine. Main
drug effects in this task were higher in the second block
(F (3,24) = 10.6; p ! 0.01) than in the first block (F (3,24) =
4.4; p ! 0.013).
Running Picture Recognition. There was a marked
decrement by both doses of scopolamine in this task in
comparison with placebo. Again, main drug effects in this
measure were higher in the second block (F (3,24) = 11.5;
p ! 0.01) than in the first block
Matching to Sample
While scopolamine caused a significant slowing of
average reaction times for simultaneous matching
(F (3,24) = 11.5; p ! 0.01) and for delayed matching
(F (3,24) = 6.1; p ! 0.003), subjects made more errors only
on delayed matching under scopolamine compared to pla-
cebo (F (3,24) = 1.1; p ! 0.353). In the main outcome mea-
sure, a combination of speed and accuracy of response,
there was again a main effect of drug in delayed matching
only (F (3,24) = 8.1; p ! 0.001), but not in simultaneous
matching (F (3,24) = 1.1; p ! 0.353). Main drug effects for
simultaneous matching and for delayed matching were
somewhat higher in the second test block as compared to
the first test block. Retest reliability under both placebo
conditions was generally higher for delayed matching as
compared to simultaneous matching. This effect was
marked for points, where reliability was Vt = 0.83 for
delayed matching, but only Vt = 0.46 for simultaneous
matching.
92 Neuropsychobiology 2003;48:87–94 Koller/Satzger/Adam/Wagner/Kathmann/
Soyka/Engel
Fig. 1. Recall of 24-word lists (lists 1–3)
under placebo 1, placebo 2, 0.3 mg of scopol-
amine and 0.6 mg of scopolamine.
Discussion
In this study, scopolamine produced profound seda-
tion, a marked and general reduction in memory perfor-
mance and a decrement in vigilance. Performance on the
span of apprehension test was only marginally affected
and no impairment was noted with respect to the accuracy
measure of the simultaneous matching task. While scopol-
amine slowed reaction time on both matching tasks, accu-
racy was reduced in the delayed matching task only. A
dose dependency was seen for all five control memory
tests, for reaction time in both matching tasks and for
observer rating of mood.
Memory impairment was recognized in both running
recognition tests. There was more impairment in the sec-
ond test block compared to the first test block.
Immediate recall was markedly reduced for the word
list at times 2 and 4. Results for free recall and most other
cognitive tests imply that the effects of scopolamine were
only slightly more pronounced in the second test block.
The drug-active time of scopolamine is 1–2.5 h after drug
injection. The effect of retrograde hypermnesia in the
memory test was not statistically significant.
In this study, scopolamine only had a marginal effect
in the three-character version of the span of apprehension
test. There was nearly no effect on the eight-character ver-
sion of the span of apprehension test. The span of appre-
hension test is a test of attentional response. A nonsignifi-
cant decrease of mean matrix size in an adaptive age-sen-
sitive version of the span of apprehension test under
1.2 mg of oral scopolamine in contrast to placebo from a
predrug score of 9.6 numerals to a postdrug score of 9.2
numerals has been reported elsewhere [4]. This leads to
the conclusion that normal aging does impair detection of
targets for eight and more characters. This can lead to the
assumption that the observed effects of scopolamine in
our study are different from those of normal aging. How-
ever, the span of apprehension test is not known to be very
sensitive to drug-induced impairments.
A significant slowing of reaction time in simultaneous
matching by scopolamine was shown. There was a main
effect of the drug in delayed matching but not in simulta-
neous matching. Opposite to these findings, scopolamine
was shown in another study to produce deficits on tests of
verbal recall, visuospatial recall, visual recognition mem-
ory, visuospatial practice, visuoperceptual function and
psychomotor speed [3]. Immediate memory, language
function, object sorting and frequency of intrusion errors
were unaffected [3]. Reanalyses of previous studies show
that pro- and anticholinergic drugs influence initial dis-
criminative ability in delayed matching to sample perfor-
mance. This was recognized to be the same effect as
shown by patients with Alzheimer’s disease [32].
In congruence with previous research, scopolamine
caused sedation [5, 10, 33] in the field of mood evalua-
tion. Scopolamine reduced performance on the contin-
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uous performance task, as shown previously [8], and
affected memory. In this study, memory effects were
shown by the immediate and delayed memory test, run-
ning word recognition, running picture recognition and
continuous visual recognition. All these tests are sensitive
to memory effects. In our results, scopolamine seems to
show clearer effects in other memory tasks used than in
the matching to sample paradigm.
In the literature, cholinergic activity has been shown to
produce a consistent pattern of deficits. Scopolamine is
known to produce impairments in long-term memory for
items no longer in the consciousness [2, 34, 35].
Also, in the field of attention, simultaneous matching
failed to show the deficits found in the continuous perfor-
mance test. In this study, the simultaneous matching task
was easier and less reliable than the delayed matching
task. Another psychometric problem is the appropriate
outcome measure for matching tasks. Memory functions
are generally expressed in terms of accuracy. For atten-
tional functions, reaction time of accuracy under speed
conditions is frequently used. In this study, we used a
combination of speed and accuracy as a main outcome
measure and presented data for reaction time and errors
separately. Since reaction time was markedly reduced
under scopolamine, this leads to conflicting results and
raises the question what is really measured by matching to
sample tasks.
Retrograde hypermnesia for items learned before sco-
polamine injection in comparison with placebo was not
found in the present study. The lack of retrograde hy-
permnesia under scopolamine was also found previously
[36] and makes a selective memory impairment due to
scopolamine less probable.
Perhaps the matching to sample paradigm is not a
powerful tool to distinguish between memory and non-
memory effects of drugs, at least in human studies. The
reason is probably an inherent confounding of task type
and task difficulty. It remains to be seen if the inclusion of
more items or more complex items, especially in the
simultaneous part of the paradigm, or shorter presenta-
tion times might overcome this problem.
In the literature, effects of scopolamine seem to be
quite specific in nature. Scopolamine is described to pro-
duce selective deficits in tests of short-term visual recog-
nition memory recognized by the matching to sample test
[20]. These effects may have implications for the pharma-
cological modeling of dementia and memory disorders.
Scopolamine-induced effects were shown to be produced
delay dependent [37]. Selective effects of scopolamine on
matching to sample tasks have been described with a
maximum 12-second delay [20]. Differences from our
results may be due to different times of delay. This shows
scopolamine effects to be very specific and to need further
evaluation.
In tests detecting attention, impairment of both speed
and accuracy induced by scopolamine has been described
[6, 13]. We were able to confirm these results by using
different kinds of tests measuring attention. This shows
that different kinds of tests measuring attention are differ-
ently sensitive to scopolamine effects.
Cholinergic blockade by scopolamine produces signifi-
cant impairment in long-term memory [2]. There is a pat-
tern of different effects of scopolamine on short-term
memory tasks. On the Brown-Peterson memory task, re-
duced performance has been shown [8]. Rusted and War-
buton [35] also reported scopolamine-induced deficits in
performance on short-term memory tasks. These results
seem to be compatible with the model of working memory
[16]. Separable components of immediate memory are
described to be responsible for distinct functions. Accord-
ing to the hypothesis of Rusted and Warbuton [38], scopol-
amine impairs the central executive component of work-
ing memory as shown by the immediate and free recall
task. These results are confirmed by our results.
The results of the present study indicate a scopol-
amine-induced reduction in both cognitive functions, at-
tention and memory, that was only partially shown by the
matching tasks. Of course, drug effects on memory cannot
be separated from drug effects on attention with definite
precision. However, some tests are known to be more sen-
sitive for memory effects than attention effects, for exam-
ple word lists, running word and running picture recogni-
tion or continuous visual recognition.
None of the tests used can be considered very specific
either for Alzheimer’s disease or for normal aging. We can
confirm results shown in the literature that scopolamine is
more effective in delayed than in simultaneous matching,
which is shown to be more specific for Alzheimer’s dis-
ease [32].
The small number of subjects and the lack of various
delays for delayed matching limit the generalizability of
the findings. More conclusive results will be reached by
the use of tasks which are carefully matched for psycho-
metric properties including sensitivity to change.
Attention and memory are very closely related. With-
out attention, a normal working memory is not possible.
Because in our results the tests used were very similar
(matching to sample paradigm with and without delay),
we can conclude that scopolamine mainly has very strong
effects on memory besides its effects on attention.
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There are not too many differences in psychometric
profiles between aging and the early phase of Alzheimer
dementia. In both cases, there are deficits in attention as
well as in memory.
In the advanced state of Alzheimer dementia, psycho-
metric profiles become more and more different from
those in normal aging, as memory functions get worse in
Alzheimer disease. In our results, scopolamine shows
strong effects which are too strong for normal aging.
Effects shown by scopolamine in our data are more pro-
nounced on memory, so that we can conclude that the sco-
polamine model is closer to Alzheimer dementia than to
normal aging.
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